Literature DB >> 8131815

Extended deep vein and inferior vena cava thrombosis in a 15-year-old boy: successful lysis with recombinant tissue-type plasminogen activator 2 weeks after onset of symptoms.

T Rosenbaum1, S Rammos, H W Kniemeyer, U Göbel.   

Abstract

We present the case of a 15-year-old boy with thrombosis of the inferior vena cava, the femoral, inguinal, and renal veins of unknown origin. Although the thrombosis was 2 weeks old, thrombolytic therapy with recombinant tissue-type plasminogen activator (maximum dosage: 0.4 mg/kg/h) was started as this appeared to be the only change to re-establish normal kidney function. After 1 week, treatment was discontinued because of generalized bleeding. At this time, the infrarenal inferior vena cava was again patent with complete lysis of all other clots. Phlebography 3 months after lysis documented an abnormal renal vein, a tubular, subhepatical stenosis of the inferior vena cava and a large collateral vessel between the inferior vena cava and the azygos vein.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8131815     DOI: 10.1007/bf01957219

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  19 in total

1.  Venous thromboembolism in infancy and childhood.

Authors:  D R Jones; I M Macintyre
Journal:  Arch Dis Child       Date:  1975-02       Impact factor: 3.791

2.  Familial thrombosis due to antithrombin 3 deficiency.

Authors:  E Marciniak; C H Farley; P A DeSimone
Journal:  Blood       Date:  1974-02       Impact factor: 22.113

3.  Spontaneous, lower-extremity venous thrombosis in children.

Authors:  R C Wise; J K Todd
Journal:  Am J Dis Child       Date:  1973-12

Review 4.  Thrombolytic therapy: current status (1).

Authors:  V J Marder; S Sherry
Journal:  N Engl J Med       Date:  1988-06-09       Impact factor: 91.245

5.  Tissue plasminogen activator for the treatment of thromboembolism in infants and children.

Authors:  M Levy; L N Benson; P E Burrows; Y Bentur; D K Strong; J Smith; D Johnson; S Jacobson; G Koren
Journal:  J Pediatr       Date:  1991-03       Impact factor: 4.406

6.  [Successful lysis of a septic thrombosis of the superior vena cava using recombinant tissue-plasminogen activator].

Authors:  D Schranz; D Haugwitz; B Zimmer; R Schumacher
Journal:  Klin Padiatr       Date:  1991 Sep-Oct       Impact factor: 1.349

7.  Requirement of heparin for arterial and venous thrombolysis with recombinant tissue-type plasminogen activator.

Authors:  H J Rapold; H R Lu; Z M Wu; H Nijs; D Collen
Journal:  Blood       Date:  1991-03-01       Impact factor: 22.113

8.  Non-iatrogenic deep vein thrombosis of lower extremities in children.

Authors:  A Gorenstein; S Katz; P Levy; M Schiller
Journal:  Z Kinderchir       Date:  1986-12

9.  [Fatal pulmonary embolism in venous thrombosis of the leg and pelvis during lysis therapy].

Authors:  W Grimm; G Schwieder; T Wagner
Journal:  Dtsch Med Wochenschr       Date:  1990-08-03       Impact factor: 0.628

10.  Left ventricular thrombus in a 2-year-old boy with cardiomyopathy: lysis with recombinant tissue-type plasminogen activator.

Authors:  O N Krogmann; R von Kries; S Rammos; H H Kramer; M Bourgeois
Journal:  Eur J Pediatr       Date:  1991-10       Impact factor: 3.183

View more
  3 in total

Review 1.  Inherited defects of the protein C anticoagulant system in childhood thrombo-embolism.

Authors:  U Nowak-Göttl; K Auberger; U Göbel; W Kreuz; R Schneppenheim; H Vielhaber; W Zenz; B Zieger
Journal:  Eur J Pediatr       Date:  1996-11       Impact factor: 3.183

2.  Heparin as a cause of thrombus progression. Heparin-associated thrombocytopenia is an important differential diagnosis in paediatric patients even with normal platelet counts.

Authors:  D Klement; S Rammos; R v Kries; W Kirschke; H W Kniemeyer; A Greinacher
Journal:  Eur J Pediatr       Date:  1996-01       Impact factor: 3.183

3.  Correlation between the expression of IL‑18 and deep venous thrombosis.

Authors:  Guangdi Li; Rudan Zhou; Xueling Zhao; Riguang Liu; Chuan Ye
Journal:  Int J Mol Med       Date:  2018-05-16       Impact factor: 4.101

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.